Medicis Lab-Derived Dermal Filler On Track For Year-End Approval – Exec
This article was originally published in The Gray Sheet
Executive Summary
Medicis will hire a 30-40 rep sales force for Q-Med's Restylane non-animal stabilized hyaluronic acid (NASHA)-based surgical wrinkle treatment in time for the product's launch, anticipated by 2004
You may also be interested in...
Mentor Hyalite dermal filler
Pivotal study commences of the non-animal stabilized hyaluronic acid dermal filler, comparing the device with Medicis' approved Restylane HA filler. Six-month data from the 12-month study will be submitted in support of a planned PMA application for facial wrinkle correction and lip augmentation. The latter application would be a first for an HA filler. Hyalite includes lidocaine anesthetic to alleviate pain during injection. Mentor acquired the device via its August 2003 acquisition of Vitrolife AB subsidiary A-Life (1"The Gray Sheet" Sept. 8, 2003, p. 19)...
Mentor Hyalite dermal filler
Pivotal study commences of the non-animal stabilized hyaluronic acid dermal filler, comparing the device with Medicis' approved Restylane HA filler. Six-month data from the 12-month study will be submitted in support of a planned PMA application for facial wrinkle correction and lip augmentation. The latter application would be a first for an HA filler. Hyalite includes lidocaine anesthetic to alleviate pain during injection. Mentor acquired the device via its August 2003 acquisition of Vitrolife AB subsidiary A-Life (1"The Gray Sheet" Sept. 8, 2003, p. 19)...
Mentor Breast Implant Sales Up 23% Despite Silicone Approval Delay
Mentor's silicone gel breast implant approval will be delayed at least until 2005 due to the political controversy surrounding the device, according to Peter Nicholson, VP-strategic planning and investor relations